Press releases

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the ”Company”) has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all outstanding shares in Disruptive Pharma Holding AB (publ) (“Disruptive Pharma”) (the “Majority Shareholders”) regarding the acquisition of their shares in Disruptive Pharma. The acquisition is intended to be carried out through a issue-in-kind, whereby the Company issues new shares (“Consideration Shares”) to the sellers in exchange for payment in the form of consideration consisting of shares in Disruptive Pharma (the ”Transaction”). Additional shareholders in Disruptive Pharma may join the agreement until the completion of the Transaction.[1] Through the Transaction, Disruptive Pharma will become a subsidiary of Guard Therapeutics. Provided that all outstanding shares in Disruptive Pharma are acquired, Disruptive Pharma’s shareholders will, following the completion of the Transaction, hold approximately 55 percent of the shares and votes in the Company, while Guard Therapeutics’ existing shareholders will hold approximately 45 percent of the shares and votes. As a result of the Transaction, the Company will change its corporate name to Disruptive Pharma AB (the Company following the completion of the Transaction is hereinafter referred to as “New Disruptive Pharma”).